Abbott news from FiercePharma
NewsEU commissioner widens pharma probe
Europe's competition commissioner is casting a wide net in her pharma-market antitrust probe. After questioning some 100 companies--including Pfizer, GlaxoSmithKline, and Read more...
Where Merck loses, Abbott gains
What's bad for Merck is good for Abbott Labs. When the FDA said "no" to Read more...
Arms twisted, pharma promises disclosure
Pharma knows that self-regulation is the best kind. That's why 12 drug and device makers have promised Sen. Chuck Grassley that they are working on plans to disclose CME grants. You know, the money Read more...
SPOTLIGHT: Abbott edges Genentech in CEO tourney
Remember the Pharma CEO tournament bracket the Wall Street Journal Health Blog came up with a few Read more...
FDA panels mull asthma drugs, stent
Big happenings in FDA Advisory Panel land today: The pediatrics committee is looking at GlaxoSmithKline's asthma drugs Serevent and Advair, while another panel preps for a closer look at Abbott's Read more...
SPOTLIGHT: NHS approves drugs
British patients on the National Health Service will get access to two intensive arthritis therapies: MabThera, made by Roche; and Humira, made by Abbott Laboratories. Patient advocacy groups have Read more...
Abbott realigns top management
Abbott Laboratories is opting to reshuffle executive responsibilities rather than filling its No. 2 management slot. The COO title will disappear when current COO Richard Gonzalez retires next Read more...
| Press ReleasesPRESS RELEASE: Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE™ V Drug Eluting Stent to FDA Advisory Committee on November 29 Data in Pre-Market Approval Application Are First Ever to Read more... PRESS RELEASE: Abbott Confirms FDA Advisory Panel to Review XIENCE™ V Drug Eluting Stent on November 29 Abbott Confirms FDA Advisory Panel to Review XIENCE™ V Drug Eluting Stent on November 29 Abbott Park, Illinois, November 5, 2007 — Abbott announced today that the U.S. Food and Drug Read more... PRESS RELEASE: New Prescription Allergy Treatment XYZAL Now Available for Fall Allergy Season New Prescription Allergy Treatment XYZAL Now Available for Fall Allergy Season ATLANTA and BRIDGEWATER, N.J., Oct. 2 -- UCB and sanofi-aventis announced today that XYZAL(R), a new once-daily Read more... |
Get more Abbott coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight